Monopar Therapeutics (MNPR) Payables: 2016-2020
Historic Payables for Monopar Therapeutics (MNPR) over the last 3 years, with Sep 2020 value amounting to $542,068.
- Monopar Therapeutics' Payables rose 12.07% to $542,068 in Q3 2020 from the same period last year, while for Sep 2020 it was $2.2 million, marking a year-over-year increase of 15.74%. This contributed to the annual value of $403,967 for FY2021, which is 9.75% down from last year.
- As of Q3 2020, Monopar Therapeutics' Payables stood at $542,068, which was up 3.10% from $525,748 recorded in Q2 2020.
- Over the past 5 years, Monopar Therapeutics' Payables peaked at $724,165 during Q4 2019, and registered a low of $64,510 during Q4 2016.
- Over the past 3 years, Monopar Therapeutics' median Payables value was $468,272 (recorded in 2019), while the average stood at $462,957.
- In the last 5 years, Monopar Therapeutics' Payables soared by 383.44% in 2017 and then fell by 23.53% in 2020.
- Quarterly analysis of 5 years shows Monopar Therapeutics' Payables stood at $64,510 in 2016, then surged by 383.44% to $311,867 in 2017, then increased by 28.12% to $399,551 in 2018, then surged by 81.24% to $724,165 in 2019, then climbed by 12.07% to $542,068 in 2020.
- Its Payables was $542,068 in Q3 2020, compared to $525,748 in Q2 2020 and $443,520 in Q1 2020.